Nuzenio

Eylea

Eylea news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 7 publisher sources 100/100 entity strength

Latest news

Biocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents - insights.citeline.cominsights.citeline.com · Fri, 07 Aug 2026 09:18:17 GMTHow AI can help shape future clinical trials - Ophthalmology Times EuropeOphthalmology Times Europe · Wed, 05 Aug 2026 16:06:52 GMTQUASAR 64-week results: aflibercept 8 mg in macular edema following RVO—Jordana G. Fein, MD, MS - Ophthalmology Times EuropeOphthalmology Times Europe · Tue, 04 Aug 2026 16:01:45 GMT'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2 - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 14:40:09 GMTBiocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg - Business WireBusiness Wire · Mon, 03 Aug 2026 11:05:00 GMTRegeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time - TIKR.comTIKR.com · Mon, 03 Aug 2026 10:24:38 GMTREGN: Q2 2026 revenue up 17% with record Dupixent, EYLEA HD, and Libtayo sales; EPS up 11% - TradingViewTradingView · Thu, 30 Jul 2026 11:18:28 GMTRegeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Fri, 07 Aug 2026 09:18:17 GMTBiocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents - insights.citeline.com
Wed, 05 Aug 2026 16:06:52 GMTHow AI can help shape future clinical trials - Ophthalmology Times Europe
Tue, 04 Aug 2026 16:01:45 GMTQUASAR 64-week results: aflibercept 8 mg in macular edema following RVO—Jordana G. Fein, MD, MS - Ophthalmology Times Europe
Tue, 04 Aug 2026 14:40:09 GMT'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2 - Fierce Pharma
Mon, 03 Aug 2026 11:05:00 GMTBiocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg - Business Wire
Mon, 03 Aug 2026 10:24:38 GMTRegeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time - TIKR.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Eylea.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.